Literature DB >> 21501599

Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation.

Ram Chandra Mishra1, Prasanthi Karna, Sushma Reddy Gundala, Vaishali Pannu, Richard A Stanton, Kamlesh Kumar Gupta, M Hope Robinson, Manu Lopus, Leslie Wilson, Maged Henary, Ritu Aneja.   

Abstract

Microtubules, composed of α/β tubulin heterodimers, represent a validated target for cancer chemotherapy. Thus, tubulin- and microtubule-binding antimitotic drugs such as taxanes and vincas are widely employed for the chemotherapeutic management of various malignancies. Although quite successful in the clinic, these drugs are associated with severe toxicity and drug resistance problems. Noscapinoids represent an emerging class of microtubule-modulating anticancer agents based upon the parent molecule noscapine, a naturally occurring non-toxic cough-suppressant opium alkaloid. Here we report in silico molecular modeling, chemical synthesis and biological evaluation of novel analogs derived by modification at position-7 of the benzofuranone ring system of noscapine. The synthesized analogs were evaluated for their tubulin polymerization activity and their biological activity was examined by their antiproliferative potential using representative cancer cell lines from varying tissue-origin [A549 (lung), CEM (lymphoma), MIA PaCa-2 (pancreatic), MCF-7 (breast) and PC-3 (prostate)]. Cell-cycle studies were performed to explore their ability to halt the cell-cycle and induce subsequent apoptosis. The varying biological activity of these analogs that differ in the nature and bulk of substituent at position-7 was rationalized utilizing predictive in silico molecular modeling.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21501599      PMCID: PMC3179862          DOI: 10.1016/j.bcp.2011.03.029

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  47 in total

1.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

Authors:  M Kavallaris; D Y Kuo; C A Burkhart; D L Regl; M D Norris; M Haber; S B Horwitz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 2.  Microtubule-interacting drugs for cancer treatment.

Authors:  Paula M Checchi; James H Nettles; Jun Zhou; James P Snyder; Harish C Joshi
Journal:  Trends Pharmacol Sci       Date:  2003-07       Impact factor: 14.819

3.  PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.

Authors:  Steven L Dixon; Alexander M Smondyrev; Eric H Knoll; Shashidhar N Rao; David E Shaw; Richard A Friesner
Journal:  J Comput Aided Mol Des       Date:  2006-11-24       Impact factor: 3.686

4.  Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.

Authors:  K Ye; Y Ke; N Keshava; J Shanks; J A Kapp; R R Tekmal; J Petros; H C Joshi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.

Authors:  M Kavallaris; A S Tait; B J Walsh; L He; S B Horwitz; M D Norris; M Haber
Journal:  Cancer Res       Date:  2001-08-01       Impact factor: 12.701

6.  Tubulin isotypes and the multigene tubulin families.

Authors:  N J Cowan; L Dudley
Journal:  Int Rev Cytol       Date:  1983

7.  Synthesis of microtubule-interfering halogenated noscapine analogs that perturb mitosis in cancer cells followed by cell death.

Authors:  Ritu Aneja; Surya N Vangapandu; Manu Lopus; Vijaya G Viswesarappa; Neerupma Dhiman; Akhilesh Verma; Ramesh Chandra; Dulal Panda; Harish C Joshi
Journal:  Biochem Pharmacol       Date:  2006-05-10       Impact factor: 5.858

8.  Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.

Authors:  Ritu Aneja; Jun Zhou; Binfei Zhou; Ramesh Chandra; Harish C Joshi
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

9.  Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses.

Authors:  Y Ke; K Ye; H E Grossniklaus; D R Archer; H C Joshi; J A Kapp
Journal:  Cancer Immunol Immunother       Date:  2000-07       Impact factor: 6.968

10.  Molecular modes of action of artesunate in tumor cell lines.

Authors:  Thomas Efferth; Axel Sauerbrey; Armin Olbrich; Erich Gebhart; Pia Rauch; H Oliver Weber; Jan G Hengstler; Marc-Eric Halatsch; Manfred Volm; Kenneth D Tew; Douglas D Ross; Jens Oliver Funk
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

View more
  13 in total

Review 1.  The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications.

Authors:  Padmashree C G Rida; Dillon LiVecche; Angela Ogden; Jun Zhou; Ritu Aneja
Journal:  Med Res Rev       Date:  2015-07-14       Impact factor: 12.944

2.  Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.

Authors:  Maged Henary; Lakshminarayana Narayana; Shazia Ahad; Sushma R Gundala; Rao Mukkavilli; Vibhuti Sharma; Eric A Owens; Yogesh Yadav; Mulpuri Nagaraju; Donald Hamelberg; Vibha Tandon; Dulal Panda; Ritu Aneja
Journal:  Biochem Pharmacol       Date:  2014-08-11       Impact factor: 5.858

Review 3.  Peloruside, laulimalide, and noscapine interactions with beta-tubulin.

Authors:  Melissa M Gajewski; Laleh Alisaraie; Jack A Tuszynski
Journal:  Pharm Res       Date:  2012-06-26       Impact factor: 4.200

4.  Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.

Authors:  Ram C Mishra; Sushma R Gundala; Prasanthi Karna; Manu Lopus; Kamlesh K Gupta; Mulpuri Nagaraju; Donald Hamelberg; Vibha Tandon; Dulal Panda; Michelle D Reid; Ritu Aneja
Journal:  Bioorg Med Chem Lett       Date:  2015-03-31       Impact factor: 2.823

5.  Metabolic pathway profiling of the derivative of important herbal component noscapine.

Authors:  Yonghua Yao; Yang Xiong
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-10-22       Impact factor: 2.441

6.  Metabolism profiling of amino-noscapine.

Authors:  Hua-Jun Qu; Yang Qian
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-20       Impact factor: 2.441

7.  Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells.

Authors:  Jitender Madan; Bharat Baruah; Mulpuri Nagaraju; Mohamed O Abdalla; Clayton Yates; Timothy Turner; Vijay Rangari; Donald Hamelberg; Ritu Aneja
Journal:  Mol Pharm       Date:  2012-04-27       Impact factor: 4.939

8.  Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.

Authors:  Elena Porcù; Attila Sipos; Giuseppe Basso; Ernest Hamel; Ruoli Bai; Verena Stempfer; Antal Udvardy; Attila Cs Bényei; Helmut Schmidhammer; Sándor Antus; Giampietro Viola
Journal:  Eur J Med Chem       Date:  2014-07-16       Impact factor: 6.514

9.  Induction of robust de novo centrosome amplification, high-grade spindle multipolarity and metaphase catastrophe: a novel chemotherapeutic approach.

Authors:  V Pannu; P C G Rida; A Ogden; R Clewley; A Cheng; P Karna; M Lopus; R C Mishra; J Zhou; R Aneja
Journal:  Cell Death Dis       Date:  2012-07-12       Impact factor: 8.469

10.  Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents.

Authors:  Naresh Kumar Manchukonda; Pradeep Kumar Naik; Seneha Santoshi; Manu Lopus; Silja Joseph; Balasubramanian Sridhar; Srinivas Kantevari
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.